These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 33493795)

  • 1. Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trials.
    Huang Y; Naidoo L; Zhang L; Carpp LN; Rudnicki E; Randhawa A; Gonzales P; McDermott A; Ledgerwood J; Lorenzo MMG; Burns D; DeCamp A; Juraska M; Mascola J; Edupuganti S; Mgodi N; Cohen M; Corey L; Andrew P; Karuna S; Gilbert PB; Mngadi K; Lazarus E
    EBioMedicine; 2021 Feb; 64():103203. PubMed ID: 33493795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial.
    Mayer KH; Seaton KE; Huang Y; Grunenberg N; Isaacs A; Allen M; Ledgerwood JE; Frank I; Sobieszczyk ME; Baden LR; Rodriguez B; Van Tieu H; Tomaras GD; Deal A; Goodman D; Bailer RT; Ferrari G; Jensen R; Hural J; Graham BS; Mascola JR; Corey L; Montefiori DC; ;
    PLoS Med; 2017 Nov; 14(11):e1002435. PubMed ID: 29136037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial.
    Crowell TA; Colby DJ; Pinyakorn S; Sacdalan C; Pagliuzza A; Intasan J; Benjapornpong K; Tangnaree K; Chomchey N; Kroon E; de Souza MS; Tovanabutra S; Rolland M; Eller MA; Paquin-Proulx D; Bolton DL; Tokarev A; Thomas R; Takata H; Trautmann L; Krebs SJ; Modjarrad K; McDermott AB; Bailer RT; Doria-Rose N; Patel B; Gorelick RJ; Fullmer BA; Schuetz A; Grandin PV; O'Connell RJ; Ledgerwood JE; Graham BS; Tressler R; Mascola JR; Chomont N; Michael NL; Robb ML; Phanuphak N; Ananworanich J;
    Lancet HIV; 2019 May; 6(5):e297-e306. PubMed ID: 31000477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase 2b Study to Evaluate the Safety and Efficacy of VRC01 Broadly Neutralizing Monoclonal Antibody in Reducing Acquisition of HIV-1 Infection in Women in Sub-Saharan Africa: Baseline Findings.
    Mgodi NM; Takuva S; Edupuganti S; Karuna S; Andrew P; Lazarus E; Garnett P; Shava E; Mukwekwerere PG; Kochar N; Marshall K; Rudnicki E; Juraska M; Anderson M; Karg C; Tindale I; Greene E; Luthuli N; Baepanye K; Hural J; Gomez Lorenzo MM; Burns D; Miner MD; Ledgerwood J; Mascola JR; Donnell D; Cohen MS; Corey L;
    J Acquir Immune Defic Syndr; 2021 May; 87(1):680-687. PubMed ID: 33587510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Feasibility and Successful Enrollment in a Proof-of-Concept HIV Prevention Trial of VRC01, a Broadly Neutralizing HIV-1 Monoclonal Antibody.
    Edupuganti S; Mgodi N; Karuna ST; Andrew P; Rudnicki E; Kochar N; deCamp A; De La Grecca R; Anderson M; Karg C; Tindale I; Greene E; Broder GB; Lucas J; Hural J; Gallardo-Cartagena JA; Gonzales P; Frank I; Sobieszczyk M; Gomez Lorenzo MM; Burns D; Anderson PL; Miner MD; Ledgerwood J; Mascola JR; Gilbert PB; Cohen MS; Corey L;
    J Acquir Immune Defic Syndr; 2021 May; 87(1):671-679. PubMed ID: 33587505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition.
    Corey L; Gilbert PB; Juraska M; Montefiori DC; Morris L; Karuna ST; Edupuganti S; Mgodi NM; deCamp AC; Rudnicki E; Huang Y; Gonzales P; Cabello R; Orrell C; Lama JR; Laher F; Lazarus EM; Sanchez J; Frank I; Hinojosa J; Sobieszczyk ME; Marshall KE; Mukwekwerere PG; Makhema J; Baden LR; Mullins JI; Williamson C; Hural J; McElrath MJ; Bentley C; Takuva S; Gomez Lorenzo MM; Burns DN; Espy N; Randhawa AK; Kochar N; Piwowar-Manning E; Donnell DJ; Sista N; Andrew P; Kublin JG; Gray G; Ledgerwood JE; Mascola JR; Cohen MS;
    N Engl J Med; 2021 Mar; 384(11):1003-1014. PubMed ID: 33730454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults.
    Ledgerwood JE; Coates EE; Yamshchikov G; Saunders JG; Holman L; Enama ME; DeZure A; Lynch RM; Gordon I; Plummer S; Hendel CS; Pegu A; Conan-Cibotti M; Sitar S; Bailer RT; Narpala S; McDermott A; Louder M; O'Dell S; Mohan S; Pandey JP; Schwartz RM; Hu Z; Koup RA; Capparelli E; Mascola JR; Graham BS;
    Clin Exp Immunol; 2015 Dec; 182(3):289-301. PubMed ID: 26332605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of serum HIV-1 neutralization titers of VRC01 in HIV-uninfected Antibody Mediated Prevention (AMP) trial participants.
    Huang Y; Zhang L; Eaton A; Mkhize NN; Carpp LN; Rudnicki E; DeCamp A; Juraska M; Randhawa A; McDermott A; Ledgerwood J; Andrew P; Karuna S; Edupuganti S; Mgodi N; Cohen M; Corey L; Mascola J; Gilbert PB; Morris L; Montefiori DC
    Hum Vaccin Immunother; 2022 Dec; 18(1):1908030. PubMed ID: 34213402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infusion Reactions After Receiving the Broadly Neutralizing Antibody VRC01 or Placebo to Reduce HIV-1 Acquisition: Results From the Phase 2b Antibody-Mediated Prevention Randomized Trials.
    Takuva S; Karuna ST; Juraska M; Rudnicki E; Edupuganti S; Anderson M; De La Grecca R; Gaudinski MR; Sehurutshi A; Orrell C; Naidoo L; Valencia J; Villela LM; Walsh SR; Andrew P; Karg C; Randhawa A; Hural J; Gomez Lorenzo MM; Burns DN; Ledgerwood J; Mascola JR; Cohen M; Corey L; Mngadi K; Mgodi NM;
    J Acquir Immune Defic Syndr; 2022 Apr; 89(4):405-413. PubMed ID: 34923559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetics analysis of VRC01, an HIV-1 broadly neutralizing monoclonal antibody, in healthy adults.
    Huang Y; Zhang L; Ledgerwood J; Grunenberg N; Bailer R; Isaacs A; Seaton K; Mayer KH; Capparelli E; Corey L; Gilbert PB
    MAbs; 2017 Jul; 9(5):792-800. PubMed ID: 28368743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety, tolerability, pharmacokinetics, and immunological activity of dual-combinations and triple-combinations of anti-HIV monoclonal antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS administered intravenously to HIV-uninfected adults: a phase 1 randomised trial.
    Sobieszczyk ME; Mannheimer S; Paez CA; Yu C; Gamble T; Theodore DA; Chege W; Yacovone M; Hanscom B; Heptinstall J; Seaton KE; Zhang L; Miner MD; Eaton A; Weiner JA; Mayer K; Kalams S; Stephenson K; Julg B; Caskey M; Nussenzweig M; Gama L; Barouch DH; Ackerman ME; Tomaras GD; Huang Y; Montefiori D;
    Lancet HIV; 2023 Oct; 10(10):e653-e662. PubMed ID: 37802566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Model Informed Development of VRC01 in Newborn Infants Using a Population Pharmacokinetics Approach.
    Li J; Nikanjam M; Cunningham CK; McFarland EJ; Coates EE; Houser KV; Lin BC; McDermott AB; Flach B; Gama L; Koup RA; Graham BS; Mascola JR; Ledgerwood JE; Capparelli EV
    Clin Pharmacol Ther; 2021 Jan; 109(1):184-192. PubMed ID: 32866318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Broadly neutralizing monoclonal antibodies for HIV prevention.
    Miner MD; Corey L; Montefiori D
    J Int AIDS Soc; 2021 Nov; 24 Suppl 7(Suppl 7):e25829. PubMed ID: 34806308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Broadly neutralizing antibody VRC01 prevents HIV-1 transmission from plasmacytoid dendritic cells to CD4 T lymphocytes.
    Su B; Lederle A; Laumond G; Ducloy C; Schmidt S; Decoville T; Moog C
    J Virol; 2014 Sep; 88(18):10975-81. PubMed ID: 24965460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rectal tissue and vaginal tissue from intravenous VRC01 recipients show protection against ex vivo HIV-1 challenge.
    Astronomo RD; Lemos MP; Narpala SR; Czartoski J; Fleming LB; Seaton KE; Prabhakaran M; Huang Y; Lu Y; Westerberg K; Zhang L; Gross MK; Hural J; Tieu HV; Baden LR; Hammer S; Frank I; Ochsenbauer C; Grunenberg N; Ledgerwood JE; Mayer K; Tomaras G; McDermott AB; McElrath MJ
    J Clin Invest; 2021 Aug; 131(16):. PubMed ID: 34166231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety, Tolerability, and Pharmacokinetics of a Long-Acting Broadly Neutralizing Human Immunodeficiency Virus Type 1 (HIV-1) Monoclonal Antibody VRC01LS in HIV-1-Exposed Newborn Infants.
    McFarland EJ; Cunningham CK; Muresan P; Capparelli EV; Perlowski C; Morgan P; Smith B; Hazra R; Purdue L; Harding PA; Theron G; Mujuru H; Agwu A; Purswani M; Rathore MH; Flach B; Taylor A; Lin BC; McDermott AB; Mascola JR; Graham BS;
    J Infect Dis; 2021 Dec; 224(11):1916-1924. PubMed ID: 34009371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic serum concentrations of VRC01 correlate with prevention of HIV-1 acquisition.
    Seaton KE; Huang Y; Karuna S; Heptinstall JR; Brackett C; Chiong K; Zhang L; Yates NL; Sampson M; Rudnicki E; Juraska M; deCamp AC; Edlefsen PT; Mullins JI; Williamson C; Rossenkhan R; Giorgi EE; Kenny A; Angier H; Randhawa A; Weiner JA; Rojas M; Sarzotti-Kelsoe M; Zhang L; Sawant S; Ackerman ME; McDermott AB; Mascola JR; Hural J; McElrath MJ; Andrew P; Hidalgo JA; Clark J; Laher F; Orrell C; Frank I; Gonzales P; Edupuganti S; Mgodi N; Corey L; Morris L; Montefiori D; Cohen MS; Gilbert PB; Tomaras GD
    EBioMedicine; 2023 Jul; 93():104590. PubMed ID: 37300931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials.
    Gilbert PB; Juraska M; deCamp AC; Karuna S; Edupuganti S; Mgodi N; Donnell DJ; Bentley C; Sista N; Andrew P; Isaacs A; Huang Y; Zhang L; Capparelli E; Kochar N; Wang J; Eshleman SH; Mayer KH; Magaret CA; Hural J; Kublin JG; Gray G; Montefiori DC; Gomez MM; Burns DN; McElrath J; Ledgerwood J; Graham BS; Mascola JR; Cohen M; Corey L
    Stat Commun Infect Dis; 2017 Jan; 9(1):. PubMed ID: 29218117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of VRC01 neutralization sensitivity by HIV-1 gp160 sequence features.
    Magaret CA; Benkeser DC; Williamson BD; Borate BR; Carpp LN; Georgiev IS; Setliff I; Dingens AS; Simon N; Carone M; Simpkins C; Montefiori D; Alter G; Yu WH; Juraska M; Edlefsen PT; Karuna S; Mgodi NM; Edugupanti S; Gilbert PB
    PLoS Comput Biol; 2019 Apr; 15(4):e1006952. PubMed ID: 30933973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A 2-4-Amino Acid Deletion in the V5 Region of HIV-1 Env gp120 Confers Viral Resistance to the Broadly Neutralizing Human Monoclonal Antibody, VRC01.
    Tachibana S; Sasaki M; Tanaka T; Inoue M; Ophinni Y; Kotaki T; Kameoka M
    AIDS Res Hum Retroviruses; 2017 Dec; 33(12):1248-1257. PubMed ID: 28903577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.